NatRevRheumatolOvjeren akaunt

@NatRevRheumatol

Tweets from the editors of Nature Reviews Rheumatology, the top review journal in the field, covering the latest advances.

London
Vrijeme pridruživanja: studeni 2011.

Tweetovi

Blokirali ste korisnika/cu @NatRevRheumatol

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NatRevRheumatol

  1. Prikvačeni tweet

    Our Key Advances in Rheumatology contains all of our articles for 2019, along with a selection of articles on related subjects so you can dive further into the topics discussed.

    Poništi
  2. | Positive results for anifrolumab in phase III SLE trial Read the original research from here Read our story here

    Poništi
  3. | EULAR updates its RA management recommendations Read the original research from here Read our story here

    Poništi
  4. | Risk variant in long noncoding RNA linked to SLE | Read the original research from here Read our news story here

    Poništi
  5. | Long-term safety of ixekizumab confirmed in Read the original research from here Read our news story here

    Poništi
  6. | Knee increases risk of all-cause mortality Read the original research from here Read our news story here

    Poništi
  7. | CD40 blockade shows promise in pSS trial | Read the original research from here Read our news story here

    Poništi
  8. | New management guidelines Read the original research from here Read our news story here

    Poništi
  9. | European consensus reached on interstitial disease in Read the original research from here Read our news story here

    Poništi
  10. Our new article from Anne Musters and Sander Tas is now online: Room for improvement in clinical trials for rare diseases Check it out at

    Poništi
  11. | on in rheumatic diseases Studies in 2019 have shown how genetic susceptibilities to can promote NET-mediated , and expanded the role for NETs Read the full article at

    Poništi
  12. | on Immunological adaptations in that modulate disease activity Read for at

    Poništi
  13. | on in Studies in 2019 reported the trends and safety of opioids in patients with or Read the full article at

    Poništi
  14. | T cell metabolism: new insights in systemic erythematosus and Check out the at

    Poništi
  15. | on in Several studies in 2019 highlight the feasibility and clinical utility of using in Check it out at

    Poništi
  16. | on immune monitoring using mass cytometry and related high-dimensional approaches Check it out at

    Poništi
  17. | on tissue analysis In 2019, new technologies for examining the molecular characteristics of specific cell have enabled advances in our understanding of the architecture of synovial tissue Read more at

    Poništi
  18. | Asymptomatic : a silent activator of the innate immune system Read the at

    Poništi
  19. | on Studies in 2019 support the effectiveness and safety of nonmedical switching and the benefits of communicating information about biosimilars to patients in a positive light. Check it out at

    Poništi
  20. Poništi
  21. Our is out now with articles on asymptomatic , T cell in , immunomodulatory mechanisms during in and next-generation immune monitoring in research.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·